414 related articles for article (PubMed ID: 11476559)
21. Detection of endometrial cancer in asymptomatic postmenopausal breast cancer patient treated with tamoxifen: a case report.
Sinawat S; Chiyabutra T; Kleabkaew P
J Med Assoc Thai; 2001 Jul; 84(7):1033-6. PubMed ID: 11759963
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature.
Machado F; Rodríguez JR; León JP; Rodríguez JR; Parrilla JJ; Abad L
Eur J Gynaecol Oncol; 2005; 26(3):257-65. PubMed ID: 15991522
[TBL] [Abstract][Full Text] [Related]
23. [Breast cancer chemoprevention. Rational, trials results and future].
Cutuli B; Lesur A; Namer M; Kerbrat P
Bull Cancer; 2009 May; 96(5):519-30. PubMed ID: 19467983
[TBL] [Abstract][Full Text] [Related]
24. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
25. Chemoprevention of breast cancer: recommendations and rationale.
Berg AO;
Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
[No Abstract] [Full Text] [Related]
26. Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: report of six cases and review of the literature.
Treilleux T; Mignotte H; Clement-Chassagne C; Guastalla P; Bailly C
Eur J Surg Oncol; 1999 Oct; 25(5):477-82. PubMed ID: 10527595
[TBL] [Abstract][Full Text] [Related]
27. [Effects of raloxifene on other organs without bone: uterus].
Nozaki M
Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132
[TBL] [Abstract][Full Text] [Related]
28. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
Burckhardt P
Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085
[TBL] [Abstract][Full Text] [Related]
29. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
30. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
31. Two good choices to prevent breast cancer: great taste, less filling.
Hortobagyi GN; Brown PH
Cancer Prev Res (Phila); 2010 Jun; 3(6):681-5. PubMed ID: 20522797
[TBL] [Abstract][Full Text] [Related]
32. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
33. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
34. [Monitoring of postmenopausal women treated with tamoxifen for breast carcinoma].
Epifani S; Lattarulo S; Maiorino R; Fabiano G
G Chir; 2000; 21(6-7):310-2. PubMed ID: 10916956
[TBL] [Abstract][Full Text] [Related]
35. Risk-reducing strategies for breast cancer--a review of recent literature.
Mokbel K
Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
[TBL] [Abstract][Full Text] [Related]
36. The tamoxifen controversy.
Crabbe WW
Oncol Nurs Forum; 1996 Jun; 23(5):761-6. PubMed ID: 8792346
[TBL] [Abstract][Full Text] [Related]
37. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
38. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist.
MacMahon B
Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-122-S1-39. PubMed ID: 9045310
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
40. [Tamoxifen and breast cancer].
Nechushtan H; Peretz T
Harefuah; 2002 Aug; 141(8):718-20, 761, 760. PubMed ID: 12222137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
